TP53 and cancer: Finally, we evaluated a unique fibroblast signature characterized by a specific gene expression pattern as candidate indicators for diagnosing the sensitivity of OC patients to ICI therapy and the presence of tumor protein p53 (TP53) mutations in pan-cancer samples.